Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

BACKGROUND: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim of this open-label, phase III CheckMate 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Omuro, Antonio, Brandes, Alba A, Carpentier, Antoine F, Idbaih, Ahmed, Reardon, David A, Cloughesy, Timothy, Sumrall, Ashley, Baehring, Joachim, van den Bent, Martin, Bähr, Oliver, Lombardi, Giuseppe, Mulholland, Paul, Tabatabai, Ghazaleh, Lassen, Ulrik, Sepulveda, Juan Manuel, Khasraw, Mustafa, Vauleon, Elodie, Muragaki, Yoshihiro, Di Giacomo, Anna Maria, Butowski, Nicholas, Roth, Patrick, Qian, Xiaozhong, Fu, Alex Z, Liu, Yanfang, Potter, Von, Chalamandaris, Alexandros-Georgios, Tatsuoka, Kay, Lim, Michael, Weller, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825306/
https://www.ncbi.nlm.nih.gov/pubmed/35419607
http://dx.doi.org/10.1093/neuonc/noac099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825306/
https://www.ncbi.nlm.nih.gov/pubmed/35419607
http://dx.doi.org/10.1093/neuonc/noac099

Ejemplares similares